A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes (Q28282265)

2

object named as

John H Alexander

0 references

author name string

Robert Frederich

1

0 references

Fred T Fiedorek

3

0 references

Mark Donovan

4

0 references

Niklas Berglind

5

0 references

Susan Harris

6

0 references

Roland Chen

7

0 references

Robert Wolf

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

8

0 references

language of work or name

English

0 references

publication date

May 2010

0 references

published in

Postgraduate Medicine

0 references

volume

122

0 references

issue

3

0 references

page(s)

16-27

0 references

cites work

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.05.2138

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.05.2138

Effects of intensive glucose lowering in type 2 diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Glucose control and vascular complications in veterans with type 2 diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

10-year follow-up of intensive glucose control in type 2 diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Benefits and risks of tight glucose control in critically ill adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

UKPDS and the legacy effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38- human cord blood hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Peritransplant ischemic injury is associated with up-regulation of stromal cell-derived factor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1alpha delivery and endogenous cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Importance of the SDF-1:CXCR4 axis in myocardial repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Genetic enhancement of stem cell engraftment, survival, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Formation of large coronary arteries by cardiac progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

B-type natriuretic peptide-induced cardioprotection against reperfusion is associated with attenuation of mitochondrial permeability transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Pretreatment with B-type natriuretic peptide protects the heart from ischemia-reperfusion injury by inhibiting myocardial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

Premature release of data from clinical trials of ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2138

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2138

1 reference

Consolidated OpenCitations Corpus – April 2017

1592017

1592017

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference